title: Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.
abstract: It is unclear whether warfarin is protective or harmful in patients with ESRD and atrial fibrillation. This state of equipoise raises the question of whether alternative anticoagulants may have a therapeutic role. We aimed to determine apixaban pharmacokinetics at steady state in patients on hemodialysis. Seven patients received apixaban 2.5 mg twice daily for 8 days. Blood samples were collected before and after apixaban administration on days 1 and 8 (nondialysis days). Significant accumulation of the drug was observed between days 1 and 8 with the 2.5-mg dose. The area under the concentration-time curve from 0 to 24 hours increased from 628 to 2054 ng h/ml (P<0.001). Trough levels increased from 45 to 132 ng/ml (P<0.001). On day 9, after a 2.5-mg dose, apixaban levels were monitored hourly during dialysis. Only 4% of the drug was removed. After a 5-day washout period, five patients received 5 mg apixaban twice daily for 8 days. The area under the concentration-time curve further increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.03), above the 90th percentile for the 5-mg dose in patients with preserved renal function. Apixaban 2.5 mg twice daily in patients on hemodialysis resulted in drug exposure comparable with that of the standard dose (5 mg twice daily) in patients with preserved renal function and might be a reasonable alternative to warfarin for stroke prevention in patients on dialysis. Apixaban 5 mg twice daily led to supratherapeutic levels in patients on hemodialysis and should be avoided.
authors.affiliation: Division of Nephrology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; and thomas.mavrakanas@mail.mcgill.ca.|Division of General Internal Medicine and.
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Mavrakanas
authors.affiliation: Department of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.
authors.forename: Caroline F
authors.initials: CF
authors.lastname: Samer
authors.affiliation: Division of Nephrology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; and.
authors.forename: Sharon J
authors.initials: SJ
authors.lastname: Nessim
authors.affiliation: Division of Nephrology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; and.
authors.forename: Gershon
authors.initials: G
authors.lastname: Frisch
authors.affiliation: Division of Nephrology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; and.
authors.forename: Mark L
authors.initials: ML
authors.lastname: Lipman
mesh_terms: D065427:Factor Xa Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011728:Pyridones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban
keywords: apixaban; atrial fibrillation; hemodialysis; pharmacokinetics